Table 1 Baseline characteristics and echocardiographic parameters of participants
Characteristic | Valuea | Missing dataa |
|---|---|---|
Demographics | ||
Age (year) | 52.3 ± 11.9 | 0 (0%) |
Female sex | 111 (82.2%) | 0 (0%) |
Female to male ratio | 4.6 | 0 (0%) |
Height (meter) | 1.58 ± 0.08 | 0 (0%) |
Weight (kilogram) | 71.0 ± 13.8 | 3 (2.2%) |
Body mass index (kg/m2) | 28.6 ± 5.3 | 3 (2.2%) |
Duration of disease (year) | 9.7 ± 9.4 | 0 (0%) |
DAS-28/ESR | 2.1 ± 0.4 | 1 (0.7%) |
SDAI | 2.7 ± 0.7 | 1 (0.7%) |
ACR functional class | 1 [1] | 1 (0.7%) |
Dyslipidemia | 30 (22.2%) | 0 (0%) |
Diabetes mellitus | 27 (20.0%) | 0 (0%) |
Hypertension | 35 (25.9%) | 0 (0%) |
Framingham score (%) | 2.7 ± 4.1 | 0 (0%) |
Medications | ||
Prednisolone | 135 (100%) | 0 (0%) |
Hydroxychloroquine | 128 (94.8%) | 0 (0%) |
Methotrexate | 125 (92.6%) | 0 (0%) |
Leflunomide | 36 (26.7%) | 0 (0%) |
Sulfasalazine | 30 (22.2%) | 0 (0%) |
Laboratory data | ||
RF (IU/mL) | 0 [2] | 0 (0%) |
ACPA (IU/mL) | 91.5 ± 115.9 | 0 (0%) |
Anti-MCV (IU/mL) | 150.1 ± 290.0 | 0 (0%) |
Total cholesterol (mg/dL) | 182.6 ± 33.9 | 0 (0%) |
Low-density lipoprotein cholesterol (mg/dL) | 106.9 ± 31.1 | 0 (0%) |
High-density lipoprotein cholesterol (mg/dL) | 50.3 ± 11.9 | 0 (0%) |
Triglyceride (mg/dL) | 137.6 ± 57.4 | 0 (0%) |
Echocardiographic indices | ||
LVEF (%) | 57.0 ± 5.4 | 0 (0%) |
PAP (mmHg) | 26.7 ± 7.8 | 10 (7.4%) |
E velocity (m/second) | 0.8 ± 0.2 | 0 (0%) |
E/e’ ratio | 9.8 ± 4.9 | 3 (2.2%) |
TAPSE (mm) | 23.2 ± 3.1 | 5 (3.7%) |
IVRT (millisecond) | 125.4 ± 19.1 | 12 (8.9%) |
RVSm (cm/s) | 12.3 ± 1.8 | 10 (7.4%) |